All In Biotech

Drug Trial Radar · NCT05460767

Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

A Phase Ia/Ib Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

504

Actual

Start

Aug 31, 2022

Primary completion

Dec 31, 2026

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter, phase Ia/Ib study. The study will evaluate the safety, tolerability and preliminary efficacy of IBI363 in subjects with advanced, relapsed or metastatic solid tumors or lymphoma, determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and thus determine the recommended phase 2 dose (RP2D).

Conditions

  • Solid Tumors or Lymphoma

Interventions

  • IBI363Biological

    a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.

  • BevacizumabDrug

    Recombinant humanized monoclonal antibody against vascular endothelial growth factor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of dose-limiting toxicity (DLT)Time frame: 21 days during the first 3-week cycle
  2. incidence of adverse events (AE), serious adverse events (SAEs), treatment-emergent AEs (TEAEs) and immune-related AEs (irAEs)Time frame: up to 90 days after the last administration
  3. Number of participants with abnormality in vital signsTime frame: up to 90 days after the last administration
  4. Number of participants with abnormality in hematology parametersTime frame: up to 90 days after the last administration
  5. Number of participants with abnormality in clinical chemistry parametersTime frame: up to 90 days after the last administration
  6. Number of participants with abnormality in routine urinalysis parametersTime frame: up to 90 days after the last administration
  7. Number of participants with abnormality in ECG parametersTime frame: up to 90 days after the last administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.